MERUS N.V. EO -09
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the… Read more
MERUS N.V. EO -09 (2GH) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, MERUS N.V. EO -09 (2GH) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
MERUS N.V. EO -09 - Net Assets Trend (None–None)
This chart illustrates how MERUS N.V. EO -09's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for MERUS N.V. EO -09 (None–None)
The table below shows the annual net assets of MERUS N.V. EO -09 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to MERUS N.V. EO -09's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
MERUS N.V. EO -09 Competitors by Market Cap
The table below lists competitors of MERUS N.V. EO -09 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Open Text Corp
NASDAQ:OTEX
|
$5.68 Billion |
|
Campbell’s Co
NYSE:CPB
|
$5.68 Billion |
|
SSR Mining Inc
NASDAQ:SSRM
|
$5.69 Billion |
|
Xinyi Glass Holdings Ltd
PINK:XYIGY
|
$5.69 Billion |
|
Games Workshop Group PLC
PINK:GMWKF
|
$5.68 Billion |
|
Evonik Industries AG
PINK:EVKIF
|
$5.68 Billion |
|
Tianshan Aluminum Group Co Ltd
SHE:002532
|
$5.67 Billion |
|
TERRENO REALTY DL -01
F:T37
|
$5.67 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in MERUS N.V. EO -09's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares MERUS N.V. EO -09's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently MERUS N.V. EO -09 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares MERUS N.V. EO -09's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| MERUS N.V. EO -09 (2GH) | €- | N/A | N/A | $5.68 Billion |
| Hanna Capital Corp (04U1) | $-79.29K | 0.00% | 0.00x | $116.52K |
| WESTMINSTER RES (08W) | $4.66 Million | -31.33% | 0.12x | $5.16 Million |
| Axonics Inc (0I3) | $570.14 Million | -10.47% | 0.16x | $3.29 Billion |
| Global Bioenergies SA (1DK) | $14.81 Million | -86.04% | 0.89x | $369.68K |
| GIEAG Immobilien AG (2GI) | $41.80 Million | 40.21% | 8.93x | $15.57K |
| 2invest AG (2INV) | $82.61 Million | -2.29% | 0.06x | $13.67 Million |
| PT Central Proteina Prima Tbk (4PT) | $3.42 Trillion | 11.74% | 1.00x | $6.90 Million |
| DGH Deutsche Grundwert Holding AG (5TR) | $0.00 | 0.00% | 0.00x | $18.45K |
| SOFTCHOICE CORP. (90Q) | $58.23 Million | -19.76% | 10.01x | $470.36 Million |
| ALBA SE (ABA) | $142.95 Million | 5.25% | 0.45x | $5.10 Million |